(Q35691909)

9 August 2017

title

Lopinavir tablet pharmacokinetics with an increased dose during pregnancy (English)

1 reference

9 August 2017

1 reference

1 reference

8

Elizabeth Smith

1 reference

9 August 2017

10

Edmund V Capparelli

1 reference

9 August 2017

Brookie M Best

1

1 reference

9 August 2017

Alice M Stek

2

1 reference

9 August 2017

Mark Mirochnick

3

1 reference

9 August 2017

Chengcheng Hu

4

1 reference

9 August 2017

Hong Li

5

1 reference

9 August 2017

Sandra K Burchett

6

1 reference

9 August 2017

Steven S Rossi

7

1 reference

9 August 2017

Jennifer S Read

9

1 reference

9 August 2017

International Maternal Pediatric Adolescent AIDS Clinical Trials Group 1026s Study Team

11

1 reference

9 August 2017

language of work or name

English

0 references

publication date

1 August 2010

1 reference

Journal of Acquired Immune Deficiency Syndromes

9 August 2017

published in

1 reference

9 August 2017

volume

54

1 reference

9 August 2017

issue

4

1 reference

9 August 2017

page(s)

381-388

1 reference

Lopinavir exposure with an increased dose during pregnancy

9 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3265163

Virological and pharmacological parameters predicting the response to lopinavir-ritonavir in heavily protease inhibitor-experienced patients

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3265163

Pharmacokinetics of antiretrovirals in pregnant women

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3265163

Quality assurance program for clinical measurement of antiretrovirals: AIDS clinical trials group proficiency testing program for pediatric and adult pharmacology laboratories

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3265163

Human immunodeficiency virus type 1 genotypic and pharmacokinetic determinants of the virological response to lopinavir-ritonavir-containing therapy in protease inhibitor-experienced patients

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3265163

ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3265163

Plasma protein binding of drugs in pregnancy

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3265163

Human immunodeficiency virus diagnostic testing of infants at clinical sites in North America: 2002-2006.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3265163

Population analysis of the pregnancy-related modifications in lopinavir pharmacokinetics and their possible consequences for dose adjustment.

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3265163

Trough concentrations of lopinavir, nelfinavir, and nevirapine with standard dosing in human immunodeficiency virus-infected pregnant women receiving 3-drug combination regimens.

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3265163

The tablet formulation of lopinavir/ritonavir provides similar bioavailability to the soft-gelatin capsule formulation with less pharmacokinetic variability and diminished food effect.

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3265163

Reduced lopinavir exposure during pregnancy

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3265163

Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A Activity) during pregnancy

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3265163

Virological, intracellular and plasma pharmacological parameters predicting response to lopinavir/ritonavir (KALEPHAR study).

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3265163

Steady-state lopinavir levels in third trimester of pregnancy

25 September 2018

1 reference

12 December 2020

Comparison of lopinavir level between the two formulations (soft-gel capsule and tablet) in HIV-infected pregnant women

1 reference

12 December 2020

Changes in serum albumin and alpha 1-acid glycoprotein concentrations during pregnancy: an analysis of fetal-maternal pairs

1 reference

12 December 2020

Plasma lopinavir trough levels in a group of pregnant women on lopinavir, ritonavir, zidovudine, and lamivudine

1 reference

12 December 2020

10.1097/QAI.0B013E3181D6C9ED

Identifiers

DOI

1 reference

9 August 2017

1 reference

9 August 2017

1 reference